ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
SuppreMol, a spin-off of Germany's Max-Planck Institute of Biochemistry, has been launched with the backing of Z-Cube, the venture-capital arm of the Italian drugmaker Zambon. SuppreMol is developing drugs that treat autoimmune diseases and allergies by acting on Fc receptors. Z-Cube says SuppreMol is the first European company it has helped launch. "To our knowledge, this is the first financing of a biotech start-up in Germany this year," adds SuppreMol CEO Peter Buckel.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X